Prothena
Market Cap
€445.6m
Last Updated
2020/02/26 22:08 UTC
Data Sources
Company Financials +
Executive Summary
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has Prothena's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 0PT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-4.3%
0PT
-8.1%
DE Biotechs
-6.8%
DE Market
1 Year Return
-5.9%
0PT
2.8%
DE Biotechs
6.5%
DE Market
Return vs Industry: 0PT underperformed the German Biotechs industry which returned 2.8% over the past year.
Return vs Market: 0PT underperformed the German Market which returned 6.5% over the past year.
Shareholder returns
| 0PT | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.3% | -8.1% | -6.8% |
| 30 Day | -3.5% | -9.4% | -3.7% |
| 90 Day | -0.9% | -4.5% | -3.6% |
| 1 Year | -5.9%-5.9% | 3.0%2.8% | 9.8%6.5% |
| 3 Year | -79.5%-79.5% | 31.3%29.9% | 6.8%-2.6% |
| 5 Year | -51.7%-51.7% | 6.9%4.6% | 12.5%-2.9% |
Price Volatility Vs. Market
How volatile is Prothena's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Prothena undervalued compared to its fair value and its price relative to the market?
1.75x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 0PT (€11.1) is trading above our estimate of fair value (€10.38)
Significantly Below Fair Value: 0PT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 0PT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 0PT is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 0PT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 0PT is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Prothena forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
20.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0PT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0PT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0PT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0PT's revenue (48.6% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 0PT's revenue (48.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0PT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Prothena performed over the past 5 years?
-13.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 0PT is currently unprofitable.
Growing Profit Margin: 0PT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 0PT is unprofitable, and losses have increased over the past 5 years at a rate of -13.2% per year.
Accelerating Growth: Unable to compare 0PT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0PT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 0PT has a negative Return on Equity (-28.46%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Prothena's financial position?
Financial Position Analysis
Short Term Liabilities: 0PT's short term assets ($378.4M) exceed its short term liabilities ($17.7M).
Long Term Liabilities: 0PT's short term assets ($378.4M) exceed its long term liabilities ($128.6M).
Debt to Equity History and Analysis
Debt Level: 0PT is debt free.
Reducing Debt: 0PT has not had any debt for past 5 years.
Balance Sheet
Inventory Level: 0PT has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 0PT's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0PT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0PT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Prothena's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 0PT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 0PT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 0PT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 0PT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 0PT's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.2yrs
Average management tenure
CEO
Gene Kinney (50yo)
3.4yrs
Tenure
US$11,396,769
Compensation
Mr. Gene G. Kinney, Ph.D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer ...
CEO Compensation Analysis
Compensation vs Market: Gene's total compensation ($USD11.40M) is above average for companies of similar size in the German market ($USD806.59K).
Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.4yrs | US$11.40m | 0.0070% $31.2k | |
| CFO & COO | 6.9yrs | US$4.96m | 0.0080% $35.7k | |
| Chief Scientific Officer | 2.7yrs | US$3.34m | no data | |
| Chief Regulatory Officer | 3.2yrs | US$3.44m | no data | |
| Chief Accounting Officer & Controller | 6.8yrs | no data | no data | |
| Chief Legal Officer & Company Secretary | 0yrs | no data | no data | |
| Head of Communications | 0yrs | no data | no data | |
| Chief Development Officer | 2.1yrs | no data | no data | |
| Consultant | 2yrs | US$1.67m | no data |
3.2yrs
Average Tenure
50yo
Average Age
Experienced Management: 0PT's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.4yrs | US$11.40m | 0.0070% $31.2k | |
| Independent Director | 6.9yrs | US$217.42k | no data | |
| Independent Director | 7.2yrs | US$221.42k | 0.0031% $13.6k | |
| Independent Chairman | 7.2yrs | US$238.42k | 0.00061% $2.7k | |
| Independent Director | 7.2yrs | US$222.42k | no data | |
| Independent Director | 6.6yrs | US$222.42k | 0.011% $47.0k | |
| Independent Director | 5.1yrs | US$207.42k | no data | |
| Director | 0.6yrs | no data | no data | |
| Director | 0.2yrs | no data | no data |
6.6yrs
Average Tenure
63yo
Average Age
Experienced Board: 0PT's board of directors are considered experienced (6.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Prothena Corporation plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Prothena Corporation plc
- Ticker: 0PT
- Exchange: DB
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$484.743m
- Listing Market Cap: US$445.624m
- Shares outstanding: 39.90m
- Website: https://www.prothena.com
Number of Employees
Location
- Prothena Corporation plc
- 77 Sir John Rogerson’s Quay
- Block C
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PRTA | NasdaqGS (Nasdaq Global Select) | Yes | Ordinary Shares | US | USD | Dec 2012 |
| 0PT | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2012 |
| 0Y3M | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | USD | Dec 2012 |
Biography
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson’s disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer’s disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/26 22:08 |
| End of Day Share Price | 2020/02/26 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.